SUCCIPRO

SUCCIPRO AIMS TO EXPLOIT THE SUCCINATE-METABOLIC-INFLAMMATORY AXIS TO CREATE NOVEL, FIRST-IN CLASS THERAPEUTICS FOR INFLAMMATORY AND METABOLIC DISEASES.

About us

SUCCIPRO is a spin-off company from IISPV and URV which aims to exploit the succinate-metabolic-inflammatory axis to create novel, first-in class therapeutics for inflammatory and metabolic diseases

MISSION

Carry out the preclinical and early clinical development of succinate-modulating therapies for inflammatory and metabolic diseases, particularly obesity, type 2 diabetes and Crohn’s disease.

VISION

Contribute to the long-term health of the people through science and provide effective solutions to people suffering from illnesses with a strong chronic inflammatory component by lowering succinate levels.

The Project

OUR STORY

SUCCIPRO is a project born from solid science on succinate pathophysiology from the DIAMET Research group, located at IISPV . SUCCIPRO is exclussively focused on succinate-modulating therapies.

PIONEERS

We are pioneers in the discovery and development of novel pharmaceuticals based on our unrivaled understanding of succinate biology and its role at the crossroad of inflammation and metabolism.

OUR TECHNOLOGY

We are using our knowledge, expertise and unique propietary tools to generate a pipeline of pre-clinical candidates with a focus on inflammatory and metabolic diseases.

Science

SUCCINATE BIOLOGY
Succinate is a normal metabolite produced both by human cells but also by gut microbiome.

Succinate is much more than a mere fueling source, since it has many additional roles derived from both intracellular but also extracellular actions through its receptor SUCNR1. This pleiotropy allows succinate to have many different and sometimes differing functions both in health and disease.
Overall, in many different contexts succinate acts as a pro-inflammatory stimulus regulating local stress, tissue damage and immune response and is also a well known oncometabolite. Importantly, succinate is elevated in the following pathological situations:

WHY SUCCINATE?
We have demonstrated that intestinal succinate is a relevant source of circulating succinate, thus setting the stage for the development of our propietary gut-restricted succinate-decreasing therapies to treat inflammatory and metabolic diseases, being Inflammatory Bowel Disease our first clinical indication.

List of Publications

Our Technology

Succinate is elevated in many pathological situations with a metabolic and/or a inflammatory component. Building on the breakthrough science from DIAMET research team, we are currently developing drugs able to reduce succinate to improve metabolism and reduce inflammation.

We have a diversified pipeline of biological proprietary succinate-modulating compounds with different Target Product Profiles.

Our first asset is a first-in-class, gut- restricted, monitorable, succinate-modulating therapy able to decrease intestinal and systemic succinate, improve inflammmation and metabolism and prevent fibrosis that has Inflamamtory Bowel Disease as a Primary Indication.

Founders

Isabel Huber

CEO

Pharmacist holding a PhD in Biochemistry from the University of Barcelona and an MBA from the Barcelona Biotechnology with more than 10 years of expertise in preclinical research

View Profile

Joan Vendrell

CMO

Clinical coordinator of the DIAMET research group. Head of Endocrinology at the Joan XXIII University Hospital and full professor at the Universitat Rovira i Virgili.

View Profile